Lymph‐Node‐Targeted Drug Delivery for Effective Immunomodulation to Prolong the Long‐Term Survival After Heart Transplantation

The chronic rejection responses and side effects of the systematic administration of immunosuppressants are the main obstacles to heart allograft and patient survival. The development of xenotransplantation also urgently requires more efficient immune regulation strategies. Herein, it is demonstrate...

Full description

Saved in:
Bibliographic Details
Published inAdvanced materials (Weinheim) Vol. 35; no. 16; pp. e2207227 - n/a
Main Authors Che, Yan‐Jia, Ren, Xiao‐He, Wang, Zhi‐Wei, Wu, Qi, Xing, Kai, Zhang, Min, Xu, Chang, Han, Di, Yuan, Shun, Zheng, Si‐Hao, Chen, Yuan‐Yang, Liao, Xin‐Ru, Shi, Feng, Zhong, Xiao‐Han, Cai, Xin, Cheng, Si‐Xue
Format Journal Article
LanguageEnglish
Published Germany Wiley Subscription Services, Inc 01.04.2023
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The chronic rejection responses and side effects of the systematic administration of immunosuppressants are the main obstacles to heart allograft and patient survival. The development of xenotransplantation also urgently requires more efficient immune regulation strategies. Herein, it is demonstrated that lymph‐node (LN)‐targeted drug delivery can realize LN‐specific immunomodulation with attenuated immune suppression on distant peripheral immune organs to effectively prolong long‐term survival after heart transplantation in a chronic murine heart transplantation model. A chemokine C‐C motif ligand 21 (CCL21) specific aptamer for LN targeting is decorated onto the surface of the hybrid nanoparticular delivery vector mainly composed of CaCO3/CaP/heparin. The targeting delivery system can dramatically enhance accumulation of the loaded immunosuppressant, fingolimod hydrochloride (FTY720), in draining lymph nodes (dLNs) for inducing powerful immune suppression. By promoting the generation of endogenous regulatory T cells (Tregs) and decreasing the proportion of effector T cells (Teffs) in dLNs after heart transplantation, the LN‐targeting strategy can effectively regulate local immune responses instead of systemic immunity, which reduces the incidence of long‐term complications. This study provides an efficient strategy to improve the survival rate after organ transplantation by precise and localized immunoregulation with minimized side effects of immunosuppression. A targeting drug delivery system decorated by a chemokine C‐C motif ligand 21 (CCL21) specific aptamer can realize lymph‐node‐targeted immunomodulation with attenuated immune suppression on distant peripheral immune organs, resulting in effectively prolonged long‐term survival after heart transplantation. This study provides an efficient strategy to achieve precise and localized immunoregulation with minimized side effects of immunosuppression.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0935-9648
1521-4095
DOI:10.1002/adma.202207227